WS17.02 Long-term efficacy of lumacaftor/ivacaftor (LUM/IVA) in children aged 2 through 5 years with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation (F/F): a phase 2, open-label extension study.
Saved in:
| Title: | WS17.02 Long-term efficacy of lumacaftor/ivacaftor (LUM/IVA) in children aged 2 through 5 years with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation (F/F): a phase 2, open-label extension study. |
|---|---|
| Authors: | Stahl, M. (AUTHOR), Roehmel, J. (AUTHOR), Eichinger, M. (AUTHOR), Doellinger, F. (AUTHOR), Naehrlich, L. (AUTHOR), Kopp, M.V. (AUTHOR), Dittrich, A.-M. (AUTHOR), Sommerburg, O. (AUTHOR), Ray, P. (AUTHOR), Maniktala, A. (AUTHOR), Duncan, M.E. (AUTHOR), Xu, T. (AUTHOR), Wu, P. (AUTHOR), Joshi, A. (AUTHOR), Mascia, M. (AUTHOR), Tian, S. (AUTHOR), Wielpütz, M.O. (AUTHOR), Mall, M.A. (AUTHOR) |
| Source: | Journal of Cystic Fibrosis. 2022 Supplement 1, Vol. 21, pS32-S33. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 15691993 |
|---|---|
| DOI: | 10.1016/S1569-1993(22)00250-8 |
